Who are H-VA dual therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infanrix TM, Comparator: Infanrix™, Healive+Healive, Boostrix TM, 23vPPV+TIV, Pentacel (DPTaP+Hib).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/h-va-dual-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

H-VA dual therapy — Competitive Intelligence Brief

H-VA dual therapy (H-VA dual therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine. Area: Immunology / Infectious Disease.

marketed Combination vaccine Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

H-VA dual therapy (H-VA dual therapy) — The First Affiliated Hospital of Nanchang University. H-VA dual therapy combines hepatitis B virus (HBV) and hepatitis A virus (HAV) immunization in a single formulation to provide dual protection against both viral infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
H-VA dual therapy TARGET	H-VA dual therapy	The First Affiliated Hospital of Nanchang University	marketed	Combination vaccine
Infanrix TM	Infanrix TM	GlaxoSmithKline	marketed	Inactivated combination vaccine
Comparator: Infanrix™	Comparator: Infanrix™	Merck Sharp & Dohme LLC	marketed	Combination vaccine (inactivated toxoid and acellular pertussis)
Healive+Healive	Healive+Healive	Sinovac Biotech Co., Ltd	marketed	Combination vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
Boostrix TM	Boostrix TM	GlaxoSmithKline	marketed	Combination vaccine (toxoid and acellular pertussis)
23vPPV+TIV	23vPPV+TIV	Jiangsu Province Centers for Disease Control and Prevention	marketed	Combination vaccine
Pentacel (DPTaP+Hib)	Pentacel (DPTaP+Hib)	The Hospital for Sick Children	marketed	Combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine class)

GlaxoSmithKline · 22 drugs in this class
Sanofi Pasteur, a Sanofi Company · 8 drugs in this class
Serum Institute of India Pvt. Ltd. · 3 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
Sanofi · 3 drugs in this class
PT Bio Farma · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). H-VA dual therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/h-va-dual-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab